Tritium labeling of antisense oligonucleotides via different conjugation agents
Abstract A novel approach to tritium-labeled antisense oligonucleotides (ASO) was established by conjugating N-succinimidyl propionate, as well as maleimide-derivatives, to the 3′-end of ASOs targeting metastasis-associated lung adenocarcinoma transcript 1 (Malat1) containing amino- or sulfhydryl-li...
Guardado en:
Autores principales: | Martin R. Edelmann, Christophe Husser, Martina B. Duschmalé, Guy Fischer, Claudia Senn, Erich Koller, Andreas Brink |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SpringerOpen
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e1253d853d5484ab910488c12140b07 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oligonucleotides
Publicado: (2003) -
Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation
por: Prithi Raguraman, et al.
Publicado: (2021) -
Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
por: Wioleta Grabowska-Pyrzewicz, et al.
Publicado: (2021) -
Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
por: Craig S. McIntosh, et al.
Publicado: (2021) -
Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′<i>O</i>Methyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Michaella Georgiadou, et al.
Publicado: (2021)